Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Overweight 1Obesity 1Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Metformin 9Inositol 5Letrozole 4Surveys and Questionnaires 3Clomiphene 3semaglutide 1mirabegron 1maltodextrin 1dapagliflozin 1Tamoxifen 1Sodium-Glucose Transporter 2 Inhibitors 1Sex Characteristics 1Positron-Emission Tomography 1Pioglitazone 1Pharmaceutical Preparations 1Liraglutide 1Hydroquinones 1Diet, Mediterranean 1Diet, Ketogenic 1Contraceptives, Oral 1Calibration 1Ascorbic Acid 1Acupuncture Therapy 15-methyltetrahydrofolate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Polycystic Ovary Syndrome × semaglutide × 90 days × Clear all
NCT06222437 2026-03-23

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Methodist Health System

Phase 1 Withdrawn

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡